<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39460293</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>30</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>T-Cell Immune Responses to SARS-CoV-2 Infection and Vaccination.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1126</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines12101126</ELocationID><Abstract><AbstractText>The innate and adaptive immune systems collaborate to detect SARS-CoV-2 infection, minimize the viral spread, and kill infected cells, ultimately leading to the resolution of the infection. The adaptive immune system develops a memory of previous encounters with the virus, providing enhanced responses when rechallenged by the same pathogen. Such immunological memory is the basis of vaccine function. Here, we review the current knowledge on the immune response to SARS-CoV-2 infection and vaccination, focusing on the pivotal role of T cells in establishing protective immunity against the virus. After providing an overview of the immune response to SARS-CoV-2 infection, we describe the main features of SARS-CoV-2-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells, including cross-reactive T cells, generated in patients with different degrees of COVID-19 severity, and of Spike-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells induced by vaccines. Finally, we discuss T-cell responses to SARS-CoV-2 variants and hybrid immunity and conclude by highlighting possible strategies to improve the efficacy of COVID-19 vaccination.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Notarbartolo</LastName><ForeName>Samuele</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-5910-4910</Identifier><AffiliationInfo><Affiliation>Infectious Diseases Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>GR-2021-12374097</GrantID><Agency>Ministero della Salute</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19 vaccine</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 infection</Keyword><Keyword MajorTopicYN="N">antigen-specific T cells</Keyword><Keyword MajorTopicYN="N">cross-reactive T cells</Keyword><Keyword MajorTopicYN="N">human T cells</Keyword><Keyword MajorTopicYN="N">hybrid immunity</Keyword><Keyword MajorTopicYN="N">immunological memory</Keyword><Keyword MajorTopicYN="N">resident memory T cells</Keyword><Keyword MajorTopicYN="N">vaccine improvement</Keyword></KeywordList><CoiStatement>The author declares no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>1</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39460293</ArticleId><ArticleId IdType="pmc">PMC11511197</ArticleId><ArticleId IdType="doi">10.3390/vaccines12101126</ArticleId><ArticleId IdType="pii">vaccines12101126</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sallusto F. Heterogeneity of Human CD4(+) T Cells against Microbes. Annu. Rev. Immunol. 2016;34:317–334. doi: 10.1146/annurev-immunol-032414-112056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-immunol-032414-112056</ArticleId><ArticleId IdType="pubmed">27168241</ArticleId></ArticleIdList></Reference><Reference><Citation>Notarbartolo S., Abrignani S. Human T lymphocytes at tumor sites. Semin. Immunopathol. 2022;44:883–901. doi: 10.1007/s00281-022-00970-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00281-022-00970-4</ArticleId><ArticleId IdType="pmc">PMC9668216</ArticleId><ArticleId IdType="pubmed">36385379</ArticleId></ArticleIdList></Reference><Reference><Citation>Farber D.L., Yudanin N.A., Restifo N.P. Human memory T cells: Generation, compartmentalization and homeostasis. Nat. Rev. Immunol. 2014;14:24–35. doi: 10.1038/nri3567.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3567</ArticleId><ArticleId IdType="pmc">PMC4032067</ArticleId><ArticleId IdType="pubmed">24336101</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganusov V.V., De Boer R.J. Do most lymphocytes in humans really reside in the gut? Trends Immunol. 2007;28:514–518. doi: 10.1016/j.it.2007.08.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2007.08.009</ArticleId><ArticleId IdType="pubmed">17964854</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh D., Yi S.V. On the origin and evolution of SARS-CoV-2. Exp. Mol. Med. 2021;53:537–547. doi: 10.1038/s12276-021-00604-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s12276-021-00604-z</ArticleId><ArticleId IdType="pmc">PMC8050477</ArticleId><ArticleId IdType="pubmed">33864026</ArticleId></ArticleIdList></Reference><Reference><Citation>Cevik M., Tate M., Lloyd O., Maraolo A.E., Schafers J., Ho A. SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: A systematic review and meta-analysis. Lancet Microbe. 2021;2:e13–e22. doi: 10.1016/S2666-5247(20)30172-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(20)30172-5</ArticleId><ArticleId IdType="pmc">PMC7837230</ArticleId><ArticleId IdType="pubmed">33521734</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiersinga W.J., Rhodes A., Cheng A.C., Peacock S.J., Prescott H.C. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020;324:782–793. doi: 10.1001/jama.2020.12839.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12839</ArticleId><ArticleId IdType="pubmed">32648899</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan W.J., Ni Z.Y., Hu Y., Liang W.H., Ou C.Q., He J.X., Liu L., Shan H., Lei C.L., Hui D.S.C., et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N. Engl. J. Med. 2020;382:1708–1720. doi: 10.1056/NEJMoa2002032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2002032</ArticleId><ArticleId IdType="pmc">PMC7092819</ArticleId><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>Lechien J.R., Chiesa-Estomba C.M., Place S., Van Laethem Y., Cabaraux P., Mat Q., Huet K., Plzak J., Horoi M., Hans S., et al. Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus disease 2019. J. Intern. Med. 2020;288:335–344. doi: 10.1111/joim.13089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joim.13089</ArticleId><ArticleId IdType="pmc">PMC7267446</ArticleId><ArticleId IdType="pubmed">32352202</ArticleId></ArticleIdList></Reference><Reference><Citation>Sette A., Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021;184:861–880. doi: 10.1016/j.cell.2021.01.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.01.007</ArticleId><ArticleId IdType="pmc">PMC7803150</ArticleId><ArticleId IdType="pubmed">33497610</ArticleId></ArticleIdList></Reference><Reference><Citation>Manfrini N., Notarbartolo S., Grifantini R., Pesce E. SARS-CoV-2: A Glance at the Innate Immune Response Elicited by Infection and Vaccination. Antibodies. 2024;13:13. doi: 10.3390/antib13010013.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antib13010013</ArticleId><ArticleId IdType="pmc">PMC10885122</ArticleId><ArticleId IdType="pubmed">38390874</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasuga Y., Zhu B., Jang K.J., Yoo J.S. Innate immune sensing of coronavirus and viral evasion strategies. Exp. Mol. Med. 2021;53:723–736. doi: 10.1038/s12276-021-00602-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s12276-021-00602-1</ArticleId><ArticleId IdType="pmc">PMC8099713</ArticleId><ArticleId IdType="pubmed">33953325</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider W.M., Chevillotte M.D., Rice C.M. Interferon-stimulated genes: A complex web of host defenses. Annu. Rev. Immunol. 2014;32:513–545. doi: 10.1146/annurev-immunol-032713-120231.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-immunol-032713-120231</ArticleId><ArticleId IdType="pmc">PMC4313732</ArticleId><ArticleId IdType="pubmed">24555472</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolumam G.A., Thomas S., Thompson L.J., Sprent J., Murali-Krishna K. Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J. Exp. Med. 2005;202:637–650. doi: 10.1084/jem.20050821.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20050821</ArticleId><ArticleId IdType="pmc">PMC2212878</ArticleId><ArticleId IdType="pubmed">16129706</ArticleId></ArticleIdList></Reference><Reference><Citation>Tough D.F., Borrow P., Sprent J. Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science. 1996;272:1947–1950. doi: 10.1126/science.272.5270.1947.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.272.5270.1947</ArticleId><ArticleId IdType="pubmed">8658169</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia H., Cao Z., Xie X., Zhang X., Chen J.Y., Wang H., Menachery V.D., Rajsbaum R., Shi P.Y. Evasion of Type I Interferon by SARS-CoV-2. Cell Rep. 2020;33:108234. doi: 10.1016/j.celrep.2020.108234.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2020.108234</ArticleId><ArticleId IdType="pmc">PMC7501843</ArticleId><ArticleId IdType="pubmed">32979938</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J.H., Koepke L., Kirchhoff F., Sparrer K.M.J. Interferon antagonists encoded by SARS-CoV-2 at a glance. Med. Microbiol. Immunol. 2022;212:125–131. doi: 10.1007/s00430-022-00734-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00430-022-00734-9</ArticleId><ArticleId IdType="pmc">PMC8976456</ArticleId><ArticleId IdType="pubmed">35366686</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco-Melo D., Nilsson-Payant B.E., Liu W.C., Uhl S., Hoagland D., Moller R., Jordan T.X., Oishi K., Panis M., Sachs D., et al. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Cell. 2020;181:1036–1045 e1039. doi: 10.1016/j.cell.2020.04.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.04.026</ArticleId><ArticleId IdType="pmc">PMC7227586</ArticleId><ArticleId IdType="pubmed">32416070</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadjadj J., Yatim N., Barnabei L., Corneau A., Boussier J., Smith N., Pere H., Charbit B., Bondet V., Chenevier-Gobeaux C., et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 2020;369:718–724. doi: 10.1126/science.abc6027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc6027</ArticleId><ArticleId IdType="pmc">PMC7402632</ArticleId><ArticleId IdType="pubmed">32661059</ArticleId></ArticleIdList></Reference><Reference><Citation>Katze M.G., Fornek J.L., Palermo R.E., Walters K.A., Korth M.J. Innate immune modulation by RNA viruses: Emerging insights from functional genomics. Nat. Rev. Immunol. 2008;8:644–654. doi: 10.1038/nri2377.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2377</ArticleId><ArticleId IdType="pmc">PMC7097543</ArticleId><ArticleId IdType="pubmed">18654572</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen G., Wu D., Guo W., Cao Y., Huang D., Wang H., Wang T., Zhang X., Chen H., Yu H., et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J. Clin. Investig. 2020;130:2620–2629. doi: 10.1172/JCI137244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI137244</ArticleId><ArticleId IdType="pmc">PMC7190990</ArticleId><ArticleId IdType="pubmed">32217835</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P., Rosen L.B., Zhang Q., Michailidis E., Hoffmann H.H., Zhang Y., Dorgham K., Philippot Q., Rosain J., Beziat V., et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370:eabd4585. doi: 10.1126/science.abd4585.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd4585</ArticleId><ArticleId IdType="pmc">PMC7857397</ArticleId><ArticleId IdType="pubmed">32972996</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q., Bastard P., Liu Z., Le Pen J., Moncada-Velez M., Chen J., Ogishi M., Sabli I.K.D., Hodeib S., Korol C., et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020;370:eabd4570. doi: 10.1126/science.abd4570.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd4570</ArticleId><ArticleId IdType="pmc">PMC7857407</ArticleId><ArticleId IdType="pubmed">32972995</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q., Bastard P., Effort C.H.G., Cobat A., Casanova J.L. Human genetic and immunological determinants of critical COVID-19 pneumonia. Nature. 2022;603:587–598. doi: 10.1038/s41586-022-04447-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04447-0</ArticleId><ArticleId IdType="pmc">PMC8957595</ArticleId><ArticleId IdType="pubmed">35090163</ArticleId></ArticleIdList></Reference><Reference><Citation>Rydyznski Moderbacher C., Ramirez S.I., Dan J.M., Grifoni A., Hastie K.M., Weiskopf D., Belanger S., Abbott R.K., Kim C., Choi J., et al. Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity. Cell. 2020;183:996–1012.e19. doi: 10.1016/j.cell.2020.09.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.09.038</ArticleId><ArticleId IdType="pmc">PMC7494270</ArticleId><ArticleId IdType="pubmed">33010815</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan A.T., Linster M., Tan C.W., Le Bert N., Chia W.N., Kunasegaran K., Zhuang Y., Tham C.Y.L., Chia A., Smith G.J.D., et al. Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients. Cell Rep. 2021;34:108728. doi: 10.1016/j.celrep.2021.108728.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.108728</ArticleId><ArticleId IdType="pmc">PMC7826084</ArticleId><ArticleId IdType="pubmed">33516277</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucas C., Klein J., Sundaram M.E., Liu F., Wong P., Silva J., Mao T., Oh J.E., Mohanty S., Huang J., et al. Delayed production of neutralizing antibodies correlates with fatal COVID-19. Nat. Med. 2021;27:1178–1186. doi: 10.1038/s41591-021-01355-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01355-0</ArticleId><ArticleId IdType="pmc">PMC8785364</ArticleId><ArticleId IdType="pubmed">33953384</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruell H., Vanshylla K., Weber T., Barnes C.O., Kreer C., Klein F. Antibody-mediated neutralization of SARS-CoV-2. Immunity. 2022;55:925–944. doi: 10.1016/j.immuni.2022.05.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2022.05.005</ArticleId><ArticleId IdType="pmc">PMC9118976</ArticleId><ArticleId IdType="pubmed">35623355</ArticleId></ArticleIdList></Reference><Reference><Citation>Afzali B., Noris M., Lambrecht B.N., Kemper C. The state of complement in COVID-19. Nat. Rev. Immunol. 2022;22:77–84. doi: 10.1038/s41577-021-00665-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-021-00665-1</ArticleId><ArticleId IdType="pmc">PMC8672651</ArticleId><ArticleId IdType="pubmed">34912108</ArticleId></ArticleIdList></Reference><Reference><Citation>Vardhana S., Baldo L., Morice W.G., 2nd, Wherry E.J. Understanding T cell responses to COVID-19 is essential for informing public health strategies. Sci. Immunol. 2022;7:eabo1303. doi: 10.1126/sciimmunol.abo1303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abo1303</ArticleId><ArticleId IdType="pmc">PMC10344642</ArticleId><ArticleId IdType="pubmed">35324269</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang J.T., Wherry E.J., Goldrath A.W. Molecular regulation of effector and memory T cell differentiation. Nat. Immunol. 2014;15:1104–1115. doi: 10.1038/ni.3031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.3031</ArticleId><ArticleId IdType="pmc">PMC4386685</ArticleId><ArticleId IdType="pubmed">25396352</ArticleId></ArticleIdList></Reference><Reference><Citation>Crotty S. T Follicular Helper Cell Biology: A Decade of Discovery and Diseases. Immunity. 2019;50:1132–1148. doi: 10.1016/j.immuni.2019.04.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2019.04.011</ArticleId><ArticleId IdType="pmc">PMC6532429</ArticleId><ArticleId IdType="pubmed">31117010</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson T.M., Li C.K., Chui C.S., Huang A.K., Perkins M., Liebner J.C., Lambkin-Williams R., Gilbert A., Oxford J., Nicholas B., et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat. Med. 2012;18:274–280. doi: 10.1038/nm.2612.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.2612</ArticleId><ArticleId IdType="pubmed">22286307</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J., Zhao J., Mangalam A.K., Channappanavar R., Fett C., Meyerholz D.K., Agnihothram S., Baric R.S., David C.S., Perlman S. Airway Memory CD4(+) T Cells Mediate Protective Immunity against Emerging Respiratory Coronaviruses. Immunity. 2016;44:1379–1391. doi: 10.1016/j.immuni.2016.05.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2016.05.006</ArticleId><ArticleId IdType="pmc">PMC4917442</ArticleId><ArticleId IdType="pubmed">27287409</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiskopf D., Bangs D.J., Sidney J., Kolla R.V., De Silva A.D., de Silva A.M., Crotty S., Peters B., Sette A. Dengue virus infection elicits highly polarized CX3CR1+ cytotoxic CD4+ T cells associated with protective immunity. Proc. Natl. Acad. Sci. USA. 2015;112:E4256–E4263. doi: 10.1073/pnas.1505956112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1505956112</ArticleId><ArticleId IdType="pmc">PMC4534238</ArticleId><ArticleId IdType="pubmed">26195744</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaneko N., Boucau J., Kuo H.H., Perugino C., Mahajan V.S., Farmer J.R., Liu H., Diefenbach T.J., Piechocka-Trocha A., Lefteri K., et al. Temporal changes in T cell subsets and expansion of cytotoxic CD4+ T cells in the lungs in severe COVID-19. Clin. Immunol. 2022;237:108991. doi: 10.1016/j.clim.2022.108991.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2022.108991</ArticleId><ArticleId IdType="pmc">PMC8961941</ArticleId><ArticleId IdType="pubmed">35364330</ArticleId></ArticleIdList></Reference><Reference><Citation>Nimmo A., Gardiner D., Ushiro-Lumb I., Ravanan R., Forsythe J.L.R. The Global Impact of COVID-19 on Solid Organ Transplantation: Two Years Into a Pandemic. Transplantation. 2022;106:1312–1329. doi: 10.1097/TP.0000000000004151.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TP.0000000000004151</ArticleId><ArticleId IdType="pmc">PMC9213067</ArticleId><ArticleId IdType="pubmed">35404911</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolla E., Weill A., Zaidan M., De Martin E., Colin De Verdiere S., Semenzato L., Zureik M., Grimaldi L. COVID-19 Hospitalization in Solid Organ Transplant Recipients on Immunosuppressive Therapy. JAMA Netw. Open. 2023;6:e2342006. doi: 10.1001/jamanetworkopen.2023.42006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2023.42006</ArticleId><ArticleId IdType="pmc">PMC10630896</ArticleId><ArticleId IdType="pubmed">37934496</ArticleId></ArticleIdList></Reference><Reference><Citation>Coll E., Fernandez-Ruiz M., Sanchez-Alvarez J.E., Martinez-Fernandez J.R., Crespo M., Gayoso J., Bada-Bosch T., Oppenheimer F., Moreso F., Lopez-Oliva M.O., et al. COVID-19 in transplant recipients: The Spanish experience. Am. J. Transplant. 2021;21:1825–1837. doi: 10.1111/ajt.16369.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ajt.16369</ArticleId><ArticleId IdType="pmc">PMC9906239</ArticleId><ArticleId IdType="pubmed">33098200</ArticleId></ArticleIdList></Reference><Reference><Citation>Kates O.S., Haydel B.M., Florman S.S., Rana M.M., Chaudhry Z.S., Ramesh M.S., Safa K., Kotton C.N., Blumberg E.A., Besharatian B.D., et al. Coronavirus Disease 2019 in Solid Organ Transplant: A Multicenter Cohort Study. Clin. Infect. Dis. 2021;73:e4090–e4099. doi: 10.1093/cid/ciaa1097.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa1097</ArticleId><ArticleId IdType="pmc">PMC7454362</ArticleId><ArticleId IdType="pubmed">32766815</ArticleId></ArticleIdList></Reference><Reference><Citation>Jering K.S., McGrath M.M., Mc Causland F.R., Claggett B., Cunningham J.W., Solomon S.D. Excess mortality in solid organ transplant recipients hospitalized with COVID-19: A large-scale comparison of SOT recipients hospitalized with or without COVID-19. Clin. Transplant. 2022;36:e14492. doi: 10.1111/ctr.14492.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ctr.14492</ArticleId><ArticleId IdType="pmc">PMC8646895</ArticleId><ArticleId IdType="pubmed">34558116</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin C.X., Moore L.W., Anjan S., Rahamimov R., Sifri C.D., Ali N.M., Morales M.K., Tsapepas D.S., Basic-Jukic N., Miller R.A., et al. Risk of Breakthrough SARS-CoV-2 Infections in Adult Transplant Recipients. Transplantation. 2021;105:e265–e266. doi: 10.1097/TP.0000000000003907.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TP.0000000000003907</ArticleId><ArticleId IdType="pmc">PMC8549120</ArticleId><ArticleId IdType="pubmed">34310531</ArticleId></ArticleIdList></Reference><Reference><Citation>Naylor K.L., Kim S.J., Smith G., McArthur E., Kwong J.C., Dixon S.N., Treleaven D., Knoll G.A. Effectiveness of first, second, and third COVID-19 vaccine doses in solid organ transplant recipients: A population-based cohort study from Canada. Am. J. Transplant. 2022;22:2228–2236. doi: 10.1111/ajt.17095.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ajt.17095</ArticleId><ArticleId IdType="pmc">PMC9347443</ArticleId><ArticleId IdType="pubmed">35578576</ArticleId></ArticleIdList></Reference><Reference><Citation>Rayner D.G., Nunes J.T., Gou D., Chu A.W.L., Dai S.C., Sheikh A., Meng D., Orchanian-Cheff A., Oss S., Rotstein C., et al. Efficacy and safety of COVID-19 vaccination in solid organ transplant recipients: A systematic review and network meta-analysis. Am. J. Transplant. 2024 doi: 10.1016/j.ajt.2024.07.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajt.2024.07.031</ArticleId><ArticleId IdType="pubmed">39094949</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyts I., Bucciol G., Quinti I., Neven B., Fischer A., Seoane E., Lopez-Granados E., Gianelli C., Robles-Marhuenda A., Jeandel P.Y., et al. Coronavirus disease 2019 in patients with inborn errors of immunity: An international study. J. Allergy Clin. Immunol. 2021;147:520–531. doi: 10.1016/j.jaci.2020.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2020.09.010</ArticleId><ArticleId IdType="pmc">PMC7832563</ArticleId><ArticleId IdType="pubmed">32980424</ArticleId></ArticleIdList></Reference><Reference><Citation>Goudouris E.S., Pinto-Mariz F., Mendonca L.O., Aranda C.S., Guimaraes R.R., Kokron C., Barros M.T., Anisio F., Alonso M.L.O., Marcelino F., et al. Outcome of SARS-CoV-2 Infection in 121 Patients with Inborn Errors of Immunity: A Cross-Sectional Study. J. Clin. Immunol. 2021;41:1479–1489. doi: 10.1007/s10875-021-01066-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-021-01066-8</ArticleId><ArticleId IdType="pmc">PMC8221557</ArticleId><ArticleId IdType="pubmed">34164762</ArticleId></ArticleIdList></Reference><Reference><Citation>Giardino G., Milito C., Lougaris V., Punziano A., Carrabba M., Cinetto F., Scarpa R., Dellepiane R.M., Ricci S., Rivalta B., et al. The Impact of SARS-CoV-2 Infection in Patients with Inborn Errors of Immunity: The Experience of the Italian Primary Immunodeficiencies Network (IPINet) J. Clin. Immunol. 2022;42:935–946. doi: 10.1007/s10875-022-01264-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-022-01264-y</ArticleId><ArticleId IdType="pmc">PMC9020753</ArticleId><ArticleId IdType="pubmed">35445287</ArticleId></ArticleIdList></Reference><Reference><Citation>Sormani M.P., De Rossi N., Schiavetti I., Carmisciano L., Cordioli C., Moiola L., Radaelli M., Immovilli P., Capobianco M., Trojano M., et al. Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. Ann. Neurol. 2021;89:780–789. doi: 10.1002/ana.26028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.26028</ArticleId><ArticleId IdType="pmc">PMC8013440</ArticleId><ArticleId IdType="pubmed">33480077</ArticleId></ArticleIdList></Reference><Reference><Citation>Langer-Gould A., Smith J.B., Li B.H., Group K.M.S. Multiple sclerosis, rituximab, and COVID-19. Ann. Clin. Transl. Neurol. 2021;8:938–943. doi: 10.1002/acn3.51342.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51342</ArticleId><ArticleId IdType="pmc">PMC8045943</ArticleId><ArticleId IdType="pubmed">33783140</ArticleId></ArticleIdList></Reference><Reference><Citation>McKay K.A., Piehl F., Englund S., He A., Langer-Gould A., Hillert J., Frisell T. Rituximab Infusion Timing, Cumulative Dose, and Hospitalization for COVID-19 in Persons With Multiple Sclerosis in Sweden. JAMA Netw. Open. 2021;4:e2136697. doi: 10.1001/jamanetworkopen.2021.36697.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.36697</ArticleId><ArticleId IdType="pmc">PMC8637249</ArticleId><ArticleId IdType="pubmed">34851401</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhaskaran K., Rentsch C.T., MacKenna B., Schultze A., Mehrkar A., Bates C.J., Eggo R.M., Morton C.E., Bacon S.C.J., Inglesby P., et al. HIV infection and COVID-19 death: A population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform. Lancet HIV. 2021;8:e24–e32. doi: 10.1016/S2352-3018(20)30305-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-3018(20)30305-2</ArticleId><ArticleId IdType="pmc">PMC7773630</ArticleId><ArticleId IdType="pubmed">33316211</ArticleId></ArticleIdList></Reference><Reference><Citation>Geretti A.M., Stockdale A.J., Kelly S.H., Cevik M., Collins S., Waters L., Villa G., Docherty A., Harrison E.M., Turtle L., et al. Outcomes of Coronavirus Disease 2019 (COVID-19) Related Hospitalization Among People With Human Immunodeficiency Virus (HIV) in the ISARIC World Health Organization (WHO) Clinical Characterization Protocol (UK): A Prospective Observational Study. Clin. Infect. Dis. 2021;73:e2095–e2106. doi: 10.1093/cid/ciaa1605.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa1605</ArticleId><ArticleId IdType="pmc">PMC7665382</ArticleId><ArticleId IdType="pubmed">33095853</ArticleId></ArticleIdList></Reference><Reference><Citation>Bange E.M., Han N.A., Wileyto P., Kim J.Y., Gouma S., Robinson J., Greenplate A.R., Hwee M.A., Porterfield F., Owoyemi O., et al. CD8(+) T cells contribute to survival in patients with COVID-19 and hematologic cancer. Nat. Med. 2021;27:1280–1289. doi: 10.1038/s41591-021-01386-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01386-7</ArticleId><ArticleId IdType="pmc">PMC8291091</ArticleId><ArticleId IdType="pubmed">34017137</ArticleId></ArticleIdList></Reference><Reference><Citation>McMahan K., Yu J., Mercado N.B., Loos C., Tostanoski L.H., Chandrashekar A., Liu J., Peter L., Atyeo C., Zhu A., et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature. 2021;590:630–634. doi: 10.1038/s41586-020-03041-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-03041-6</ArticleId><ArticleId IdType="pmc">PMC7906955</ArticleId><ArticleId IdType="pubmed">33276369</ArticleId></ArticleIdList></Reference><Reference><Citation>Swadling L., Diniz M.O., Schmidt N.M., Amin O.E., Chandran A., Shaw E., Pade C., Gibbons J.M., Le Bert N., Tan A.T., et al. Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2. Nature. 2022;601:110–117. doi: 10.1038/s41586-021-04186-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04186-8</ArticleId><ArticleId IdType="pmc">PMC8732273</ArticleId><ArticleId IdType="pubmed">34758478</ArticleId></ArticleIdList></Reference><Reference><Citation>Shomuradova A.S., Vagida M.S., Sheetikov S.A., Zornikova K.V., Kiryukhin D., Titov A., Peshkova I.O., Khmelevskaya A., Dianov D.V., Malasheva M., et al. SARS-CoV-2 Epitopes Are Recognized by a Public and Diverse Repertoire of Human T Cell Receptors. Immunity. 2020;53:1245–1257.e5. doi: 10.1016/j.immuni.2020.11.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2020.11.004</ArticleId><ArticleId IdType="pmc">PMC7664363</ArticleId><ArticleId IdType="pubmed">33326767</ArticleId></ArticleIdList></Reference><Reference><Citation>Notarbartolo S., Ranzani V., Bandera A., Gruarin P., Bevilacqua V., Putignano A.R., Gobbini A., Galeota E., Manara C., Bombaci M., et al. Integrated longitudinal immunophenotypic, transcriptional and repertoire analyses delineate immune responses in COVID-19 patients. Sci. Immunol. 2021;6:eabg5021. doi: 10.1126/sciimmunol.abg5021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abg5021</ArticleId><ArticleId IdType="pubmed">34376481</ArticleId></ArticleIdList></Reference><Reference><Citation>Welsh R.M., Selin L.K., Szomolanyi-Tsuda E. Immunological memory to viral infections. Annu. Rev. Immunol. 2004;22:711–743. doi: 10.1146/annurev.immunol.22.012703.104527.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.immunol.22.012703.104527</ArticleId><ArticleId IdType="pubmed">15032594</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian Y., Carpp L.N., Miller H.E.R., Zager M., Newell E.W., Gottardo R. Single-cell immunology of SARS-CoV-2 infection. Nat. Biotechnol. 2022;40:30–41. doi: 10.1038/s41587-021-01131-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-021-01131-y</ArticleId><ArticleId IdType="pmc">PMC9414121</ArticleId><ArticleId IdType="pubmed">34931002</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathew D., Giles J.R., Baxter A.E., Oldridge D.A., Greenplate A.R., Wu J.E., Alanio C., Kuri-Cervantes L., Pampena M.B., D’Andrea K., et al. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science. 2020;369:eabc8511. doi: 10.1126/science.abc8511.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc8511</ArticleId><ArticleId IdType="pmc">PMC7402624</ArticleId><ArticleId IdType="pubmed">32669297</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzoni A., Salvati L., Maggi L., Capone M., Vanni A., Spinicci M., Mencarini J., Caporale R., Peruzzi B., Antonelli A., et al. Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent. J. Clin. Investig. 2020;130:4694–4703. doi: 10.1172/JCI138554.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI138554</ArticleId><ArticleId IdType="pmc">PMC7456250</ArticleId><ArticleId IdType="pubmed">32463803</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao M., Liu Y., Yuan J., Wen Y., Xu G., Zhao J., Cheng L., Li J., Wang X., Wang F., et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat. Med. 2020;26:842–844. doi: 10.1038/s41591-020-0901-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0901-9</ArticleId><ArticleId IdType="pubmed">32398875</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucas C., Wong P., Klein J., Castro T.B.R., Silva J., Sundaram M., Ellingson M.K., Mao T., Oh J.E., Israelow B., et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature. 2020;584:463–469. doi: 10.1038/s41586-020-2588-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2588-y</ArticleId><ArticleId IdType="pmc">PMC7477538</ArticleId><ArticleId IdType="pubmed">32717743</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C.K., Wu H., Yan H., Ma S., Wang L., Zhang M., Tang X., Temperton N.J., Weiss R.A., Brenchley J.M., et al. T cell responses to whole SARS coronavirus in humans. J. Immunol. 2008;181:5490–5500. doi: 10.4049/jimmunol.181.8.5490.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.181.8.5490</ArticleId><ArticleId IdType="pmc">PMC2683413</ArticleId><ArticleId IdType="pubmed">18832706</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham M.B., Braciale V.L., Braciale T.J. Influenza virus-specific CD4+ T helper type 2 T lymphocytes do not promote recovery from experimental virus infection. J. Exp. Med. 1994;180:1273–1282. doi: 10.1084/jem.180.4.1273.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.180.4.1273</ArticleId><ArticleId IdType="pmc">PMC2191682</ArticleId><ArticleId IdType="pubmed">7931062</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartleson J.M., Radenkovic D., Covarrubias A.J., Furman D., Winer D.A., Verdin E. SARS-CoV-2, COVID-19 and the Ageing Immune System. Nat. Aging. 2021;1:769–782. doi: 10.1038/s43587-021-00114-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s43587-021-00114-7</ArticleId><ArticleId IdType="pmc">PMC8570568</ArticleId><ArticleId IdType="pubmed">34746804</ArticleId></ArticleIdList></Reference><Reference><Citation>Britanova O.V., Putintseva E.V., Shugay M., Merzlyak E.M., Turchaninova M.A., Staroverov D.B., Bolotin D.A., Lukyanov S., Bogdanova E.A., Mamedov I.Z., et al. Age-related decrease in TCR repertoire diversity measured with deep and normalized sequence profiling. J. Immunol. 2014;192:2689–2698. doi: 10.4049/jimmunol.1302064.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1302064</ArticleId><ArticleId IdType="pubmed">24510963</ArticleId></ArticleIdList></Reference><Reference><Citation>Goronzy J.J., Weyand C.M. Mechanisms underlying T cell ageing. Nat. Rev. Immunol. 2019;19:573–583. doi: 10.1038/s41577-019-0180-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-019-0180-1</ArticleId><ArticleId IdType="pmc">PMC7584388</ArticleId><ArticleId IdType="pubmed">31186548</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicoli F., Clave E., Wanke K., von Braun A., Bondet V., Alanio C., Douay C., Baque M., Lependu C., Marconi P., et al. Primary immune responses are negatively impacted by persistent herpesvirus infections in older people: Results from an observational study on healthy subjects and a vaccination trial on subjects aged more than 70 years old. EBioMedicine. 2022;76:103852. doi: 10.1016/j.ebiom.2022.103852.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2022.103852</ArticleId><ArticleId IdType="pmc">PMC8818547</ArticleId><ArticleId IdType="pubmed">35114631</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim T.S., Shin E.C. The activation of bystander CD8(+) T cells and their roles in viral infection. Exp. Mol. Med. 2019;51:1–9. doi: 10.1038/s12276-019-0316-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s12276-019-0316-1</ArticleId><ArticleId IdType="pmc">PMC6906361</ArticleId><ArticleId IdType="pubmed">31827070</ArticleId></ArticleIdList></Reference><Reference><Citation>Sottile R., Panjwani M.K., Lau C.M., Daniyan A.F., Tanaka K., Barker J.N., Brentjens R.J., Sun J.C., Le Luduec J.B., Hsu K.C. Human cytomegalovirus expands a CD8(+) T cell population with loss of BCL11B expression and gain of NK cell identity. Sci. Immunol. 2021;6:eabe6968. doi: 10.1126/sciimmunol.abe6968.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abe6968</ArticleId><ArticleId IdType="pmc">PMC8601152</ArticleId><ArticleId IdType="pubmed">34559552</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergamaschi L., Mescia F., Turner L., Hanson A.L., Kotagiri P., Dunmore B.J., Ruffieux H., De Sa A., Huhn O., Morgan M.D., et al. Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease. Immunity. 2021;54:1257–1275 e1258. doi: 10.1016/j.immuni.2021.05.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2021.05.010</ArticleId><ArticleId IdType="pmc">PMC8125900</ArticleId><ArticleId IdType="pubmed">34051148</ArticleId></ArticleIdList></Reference><Reference><Citation>Georg P., Astaburuaga-Garcia R., Bonaguro L., Brumhard S., Michalick L., Lippert L.J., Kostevc T., Gabel C., Schneider M., Streitz M., et al. Complement activation induces excessive T cell cytotoxicity in severe COVID-19. Cell. 2022;185:493–512.e25. doi: 10.1016/j.cell.2021.12.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.12.040</ArticleId><ArticleId IdType="pmc">PMC8712270</ArticleId><ArticleId IdType="pubmed">35032429</ArticleId></ArticleIdList></Reference><Reference><Citation>Grifoni A., Sidney J., Vita R., Peters B., Crotty S., Weiskopf D., Sette A. SARS-CoV-2 human T cell epitopes: Adaptive immune response against COVID-19. Cell Host Microbe. 2021;29:1076–1092. doi: 10.1016/j.chom.2021.05.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2021.05.010</ArticleId><ArticleId IdType="pmc">PMC8139264</ArticleId><ArticleId IdType="pubmed">34237248</ArticleId></ArticleIdList></Reference><Reference><Citation>Vita R., Mahajan S., Overton J.A., Dhanda S.K., Martini S., Cantrell J.R., Wheeler D.K., Sette A., Peters B. The Immune Epitope Database (IEDB): 2018 update. Nucleic Acids Res. 2019;47:D339–D343. doi: 10.1093/nar/gky1006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gky1006</ArticleId><ArticleId IdType="pmc">PMC6324067</ArticleId><ArticleId IdType="pubmed">30357391</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarke A., Sidney J., Kidd C.K., Dan J.M., Ramirez S.I., Yu E.D., Mateus J., da Silva Antunes R., Moore E., Rubiro P., et al. Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases. Cell Rep. Med. 2021;2:100204. doi: 10.1016/j.xcrm.2021.100204.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2021.100204</ArticleId><ArticleId IdType="pmc">PMC7837622</ArticleId><ArticleId IdType="pubmed">33521695</ArticleId></ArticleIdList></Reference><Reference><Citation>Low J.S., Vaqueirinho D., Mele F., Foglierini M., Jerak J., Perotti M., Jarrossay D., Jovic S., Perez L., Cacciatore R., et al. Clonal analysis of immunodominance and cross-reactivity of the CD4 T cell response to SARS-CoV-2. Science. 2021;372:1336–1341. doi: 10.1126/science.abg8985.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abg8985</ArticleId><ArticleId IdType="pmc">PMC8168615</ArticleId><ArticleId IdType="pubmed">34006597</ArticleId></ArticleIdList></Reference><Reference><Citation>Grifoni A., Weiskopf D., Ramirez S.I., Mateus J., Dan J.M., Moderbacher C.R., Rawlings S.A., Sutherland A., Premkumar L., Jadi R.S., et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell. 2020;181:1489–1501.e15. doi: 10.1016/j.cell.2020.05.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.05.015</ArticleId><ArticleId IdType="pmc">PMC7237901</ArticleId><ArticleId IdType="pubmed">32473127</ArticleId></ArticleIdList></Reference><Reference><Citation>Braun J., Loyal L., Frentsch M., Wendisch D., Georg P., Kurth F., Hippenstiel S., Dingeldey M., Kruse B., Fauchere F., et al. SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. Nature. 2020;587:270–274. doi: 10.1038/s41586-020-2598-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2598-9</ArticleId><ArticleId IdType="pubmed">32726801</ArticleId></ArticleIdList></Reference><Reference><Citation>Mateus J., Grifoni A., Tarke A., Sidney J., Ramirez S.I., Dan J.M., Burger Z.C., Rawlings S.A., Smith D.M., Phillips E., et al. Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. Science. 2020;370:89–94. doi: 10.1126/science.abd3871.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd3871</ArticleId><ArticleId IdType="pmc">PMC7574914</ArticleId><ArticleId IdType="pubmed">32753554</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelde A., Bilich T., Heitmann J.S., Maringer Y., Salih H.R., Roerden M., Lubke M., Bauer J., Rieth J., Wacker M., et al. SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition. Nat. Immunol. 2021;22:74–85. doi: 10.1038/s41590-020-00808-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-020-00808-x</ArticleId><ArticleId IdType="pubmed">32999467</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacher P., Rosati E., Esser D., Martini G.R., Saggau C., Schiminsky E., Dargvainiene J., Schroder I., Wieters I., Khodamoradi Y., et al. Low-Avidity CD4(+) T Cell Responses to SARS-CoV-2 in Unexposed Individuals and Humans with Severe COVID-19. Immunity. 2020;53:1258–1271.e5. doi: 10.1016/j.immuni.2020.11.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2020.11.016</ArticleId><ArticleId IdType="pmc">PMC7689350</ArticleId><ArticleId IdType="pubmed">33296686</ArticleId></ArticleIdList></Reference><Reference><Citation>Dykema A.G., Zhang B., Woldemeskel B.A., Garliss C.C., Cheung L.S., Choudhury D., Zhang J., Aparicio L., Bom S., Rashid R., et al. Functional characterization of CD4+ T cell receptors crossreactive for SARS-CoV-2 and endemic coronaviruses. J. Clin. Investig. 2021;131:e146922. doi: 10.1172/JCI146922.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI146922</ArticleId><ArticleId IdType="pmc">PMC8121515</ArticleId><ArticleId IdType="pubmed">33830946</ArticleId></ArticleIdList></Reference><Reference><Citation>Pothast C.R., Dijkland R.C., Thaler M., Hagedoorn R.S., Kester M.G.D., Wouters A.K., Hiemstra P.S., van Hemert M.J., Gras S., Falkenburg J.H.F., et al. SARS-CoV-2-specific CD4(+) and CD8(+) T cell responses can originate from cross-reactive CMV-specific T cells. Elife. 2022;11:e82050. doi: 10.7554/eLife.82050.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.82050</ArticleId><ArticleId IdType="pmc">PMC9822249</ArticleId><ArticleId IdType="pubmed">36408799</ArticleId></ArticleIdList></Reference><Reference><Citation>Sagar M., Reifler K., Rossi M., Miller N.S., Sinha P., White L.F., Mizgerd J.P. Recent endemic coronavirus infection is associated with less-severe COVID-19. J. Clin. Investig. 2021;131:e143380. doi: 10.1172/JCI143380.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI143380</ArticleId><ArticleId IdType="pmc">PMC7773342</ArticleId><ArticleId IdType="pubmed">32997649</ArticleId></ArticleIdList></Reference><Reference><Citation>Loyal L., Braun J., Henze L., Kruse B., Dingeldey M., Reimer U., Kern F., Schwarz T., Mangold M., Unger C., et al. Cross-reactive CD4(+) T cells enhance SARS-CoV-2 immune responses upon infection and vaccination. Science. 2021;374:eabh1823. doi: 10.1126/science.abh1823.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abh1823</ArticleId><ArticleId IdType="pmc">PMC10026850</ArticleId><ArticleId IdType="pubmed">34465633</ArticleId></ArticleIdList></Reference><Reference><Citation>Mallajosyula V., Ganjavi C., Chakraborty S., McSween A.M., Pavlovitch-Bedzyk A.J., Wilhelmy J., Nau A., Manohar M., Nadeau K.C., Davis M.M. CD8(+) T cells specific for conserved coronavirus epitopes correlate with milder disease in COVID-19 patients. Sci. Immunol. 2021;6:eabg5669. doi: 10.1126/sciimmunol.abg5669.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abg5669</ArticleId><ArticleId IdType="pmc">PMC8975171</ArticleId><ArticleId IdType="pubmed">34210785</ArticleId></ArticleIdList></Reference><Reference><Citation>Moss P. The T cell immune response against SARS-CoV-2. Nat. Immunol. 2022;23:186–193. doi: 10.1038/s41590-021-01122-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01122-w</ArticleId><ArticleId IdType="pubmed">35105982</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng Y., Felce S.L., Dong D., Penkava F., Mentzer A.J., Yao X., Liu G., Yin Z., Chen J.L., Lu Y., et al. An immunodominant NP105-113-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease. Nat. Immunol. 2022;23:50–61. doi: 10.1038/s41590-021-01084-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01084-z</ArticleId><ArticleId IdType="pmc">PMC8709787</ArticleId><ArticleId IdType="pubmed">34853448</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen T.H.O., Rowntree L.C., Petersen J., Chua B.Y., Hensen L., Kedzierski L., van de Sandt C.E., Chaurasia P., Tan H.X., Habel J.R., et al. CD8(+) T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope display high naive precursor frequency and TCR promiscuity. Immunity. 2021;54:1066–1082.e5. doi: 10.1016/j.immuni.2021.04.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2021.04.009</ArticleId><ArticleId IdType="pmc">PMC8049468</ArticleId><ArticleId IdType="pubmed">33951417</ArticleId></ArticleIdList></Reference><Reference><Citation>Kared H., Redd A.D., Bloch E.M., Bonny T.S., Sumatoh H., Kairi F., Carbajo D., Abel B., Newell E.W., Bettinotti M.P., et al. SARS-CoV-2-specific CD8+ T cell responses in convalescent COVID-19 individuals. J. Clin. Investig. 2021;131:e145476. doi: 10.1172/JCI145476.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI145476</ArticleId><ArticleId IdType="pmc">PMC7919723</ArticleId><ArticleId IdType="pubmed">33427749</ArticleId></ArticleIdList></Reference><Reference><Citation>Saini S.K., Hersby D.S., Tamhane T., Povlsen H.R., Amaya Hernandez S.P., Nielsen M., Gang A.O., Hadrup S.R. SARS-CoV-2 genome-wide T cell epitope mapping reveals immunodominance and substantial CD8(+) T cell activation in COVID-19 patients. Sci. Immunol. 2021;6:eabf7550. doi: 10.1126/sciimmunol.abf7550.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abf7550</ArticleId><ArticleId IdType="pmc">PMC8139428</ArticleId><ArticleId IdType="pubmed">33853928</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauer S.A., Grantz K.H., Bi Q., Jones F.K., Zheng Q., Meredith H.R., Azman A.S., Reich N.G., Lessler J. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Ann. Intern. Med. 2020;172:577–582. doi: 10.7326/M20-0504.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M20-0504</ArticleId><ArticleId IdType="pmc">PMC7081172</ArticleId><ArticleId IdType="pubmed">32150748</ArticleId></ArticleIdList></Reference><Reference><Citation>Killingley B., Mann A.J., Kalinova M., Boyers A., Goonawardane N., Zhou J., Lindsell K., Hare S.S., Brown J., Frise R., et al. Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults. Nat. Med. 2022;28:1031–1041. doi: 10.1038/s41591-022-01780-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01780-9</ArticleId><ArticleId IdType="pubmed">35361992</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiskopf D., Schmitz K.S., Raadsen M.P., Grifoni A., Okba N.M.A., Endeman H., van den Akker J.P.C., Molenkamp R., Koopmans M.P.G., van Gorp E.C.M., et al. Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome. Sci. Immunol. 2020;5:eabd2071. doi: 10.1126/sciimmunol.abd2071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abd2071</ArticleId><ArticleId IdType="pmc">PMC7319493</ArticleId><ArticleId IdType="pubmed">32591408</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindeboom R.G.H., Worlock K.B., Dratva L.M., Yoshida M., Scobie D., Wagstaffe H.R., Richardson L., Wilbrey-Clark A., Barnes J.L., Kretschmer L., et al. Human SARS-CoV-2 challenge uncovers local and systemic response dynamics. Nature. 2024;631:189–198. doi: 10.1038/s41586-024-07575-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-024-07575-x</ArticleId><ArticleId IdType="pmc">PMC11222146</ArticleId><ArticleId IdType="pubmed">38898278</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou R., To K.K., Wong Y.C., Liu L., Zhou B., Li X., Huang H., Mo Y., Luk T.Y., Lau T.T., et al. Acute SARS-CoV-2 Infection Impairs Dendritic Cell and T Cell Responses. Immunity. 2020;53:864–877.e5. doi: 10.1016/j.immuni.2020.07.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2020.07.026</ArticleId><ArticleId IdType="pmc">PMC7402670</ArticleId><ArticleId IdType="pubmed">32791036</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekine T., Perez-Potti A., Rivera-Ballesteros O., Stralin K., Gorin J.B., Olsson A., Llewellyn-Lacey S., Kamal H., Bogdanovic G., Muschiol S., et al. Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. Cell. 2020;183:158–168.e14. doi: 10.1016/j.cell.2020.08.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.08.017</ArticleId><ArticleId IdType="pmc">PMC7427556</ArticleId><ArticleId IdType="pubmed">32979941</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Bert N., Tan A.T., Kunasegaran K., Tham C.Y.L., Hafezi M., Chia A., Chng M.H.Y., Lin M., Tan N., Linster M., et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. 2020;584:457–462. doi: 10.1038/s41586-020-2550-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2550-z</ArticleId><ArticleId IdType="pubmed">32668444</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Bert N., Clapham H.E., Tan A.T., Chia W.N., Tham C.Y.L., Lim J.M., Kunasegaran K., Tan L.W.L., Dutertre C.A., Shankar N., et al. Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection. J. Exp. Med. 2021;218:e20202617. doi: 10.1084/jem.20202617.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20202617</ArticleId><ArticleId IdType="pmc">PMC7927662</ArticleId><ArticleId IdType="pubmed">33646265</ArticleId></ArticleIdList></Reference><Reference><Citation>Meckiff B.J., Ramirez-Suastegui C., Fajardo V., Chee S.J., Kusnadi A., Simon H., Eschweiler S., Grifoni A., Pelosi E., Weiskopf D., et al. Imbalance of Regulatory and Cytotoxic SARS-CoV-2-Reactive CD4(+) T Cells in COVID-19. Cell. 2020;183:1340–1353.e16. doi: 10.1016/j.cell.2020.10.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.10.001</ArticleId><ArticleId IdType="pmc">PMC7534589</ArticleId><ArticleId IdType="pubmed">33096020</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Ploeg K., Kirosingh A.S., Mori D.A.M., Chakraborty S., Hu Z., Sievers B.L., Jacobson K.B., Bonilla H., Parsonnet J., Andrews J.R., et al. TNF-alpha(+) CD4(+) T cells dominate the SARS-CoV-2 specific T cell response in COVID-19 outpatients and are associated with durable antibodies. Cell Rep. Med. 2022;3:100640. doi: 10.1016/j.xcrm.2022.100640.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2022.100640</ArticleId><ArticleId IdType="pmc">PMC9061140</ArticleId><ArticleId IdType="pubmed">35588734</ArticleId></ArticleIdList></Reference><Reference><Citation>Boppana S., Qin K., Files J.K., Russell R.M., Stoltz R., Bibollet-Ruche F., Bansal A., Erdmann N., Hahn B.H., Goepfert P.A. SARS-CoV-2-specific circulating T follicular helper cells correlate with neutralizing antibodies and increase during early convalescence. PLoS Pathog. 2021;17:e1009761. doi: 10.1371/journal.ppat.1009761.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1009761</ArticleId><ArticleId IdType="pmc">PMC8318272</ArticleId><ArticleId IdType="pubmed">34270631</ArticleId></ArticleIdList></Reference><Reference><Citation>Koutsakos M., Rowntree L.C., Hensen L., Chua B.Y., van de Sandt C.E., Habel J.R., Zhang W., Jia X., Kedzierski L., Ashhurst T.M., et al. Integrated immune dynamics define correlates of COVID-19 severity and antibody responses. Cell Rep. Med. 2021;2:100208. doi: 10.1016/j.xcrm.2021.100208.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2021.100208</ArticleId><ArticleId IdType="pmc">PMC7862905</ArticleId><ArticleId IdType="pubmed">33564749</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaneko N., Kuo H.H., Boucau J., Farmer J.R., Allard-Chamard H., Mahajan V.S., Piechocka-Trocha A., Lefteri K., Osborn M., Bals J., et al. Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19. Cell. 2020;183:143–157.e13. doi: 10.1016/j.cell.2020.08.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.08.025</ArticleId><ArticleId IdType="pmc">PMC7437499</ArticleId><ArticleId IdType="pubmed">32877699</ArticleId></ArticleIdList></Reference><Reference><Citation>Rha M.S., Jeong H.W., Ko J.H., Choi S.J., Seo I.H., Lee J.S., Sa M., Kim A.R., Joo E.J., Ahn J.Y., et al. PD-1-Expressing SARS-CoV-2-Specific CD8(+) T Cells Are Not Exhausted, but Functional in Patients with COVID-19. Immunity. 2021;54:44–52.43. doi: 10.1016/j.immuni.2020.12.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2020.12.002</ArticleId><ArticleId IdType="pmc">PMC7834198</ArticleId><ArticleId IdType="pubmed">33338412</ArticleId></ArticleIdList></Reference><Reference><Citation>Adamo S., Michler J., Zurbuchen Y., Cervia C., Taeschler P., Raeber M.E., Baghai Sain S., Nilsson J., Moor A.E., Boyman O. Signature of long-lived memory CD8(+) T cells in acute SARS-CoV-2 infection. Nature. 2022;602:148–155. doi: 10.1038/s41586-021-04280-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04280-x</ArticleId><ArticleId IdType="pmc">PMC8810382</ArticleId><ArticleId IdType="pubmed">34875673</ArticleId></ArticleIdList></Reference><Reference><Citation>Rha M.S., Shin E.C. Activation or exhaustion of CD8(+) T cells in patients with COVID-19. Cell Mol. Immunol. 2021;18:2325–2333. doi: 10.1038/s41423-021-00750-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-021-00750-4</ArticleId><ArticleId IdType="pmc">PMC8374113</ArticleId><ArticleId IdType="pubmed">34413488</ArticleId></ArticleIdList></Reference><Reference><Citation>Minervina A.A., Komech E.A., Titov A., Bensouda Koraichi M., Rosati E., Mamedov I.Z., Franke A., Efimov G.A., Chudakov D.M., Mora T., et al. Longitudinal high-throughput TCR repertoire profiling reveals the dynamics of T-cell memory formation after mild COVID-19 infection. Elife. 2021;10:e63502. doi: 10.7554/eLife.63502.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.63502</ArticleId><ArticleId IdType="pmc">PMC7806265</ArticleId><ArticleId IdType="pubmed">33399535</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferretti A.P., Kula T., Wang Y., Nguyen D.M.V., Weinheimer A., Dunlap G.S., Xu Q., Nabilsi N., Perullo C.R., Cristofaro A.W., et al. Unbiased Screens Show CD8(+) T Cells of COVID-19 Patients Recognize Shared Epitopes in SARS-CoV-2 that Largely Reside outside the Spike Protein. Immunity. 2020;53:1095–1107.e3. doi: 10.1016/j.immuni.2020.10.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2020.10.006</ArticleId><ArticleId IdType="pmc">PMC7574860</ArticleId><ArticleId IdType="pubmed">33128877</ArticleId></ArticleIdList></Reference><Reference><Citation>Dan J.M., Mateus J., Kato Y., Hastie K.M., Yu E.D., Faliti C.E., Grifoni A., Ramirez S.I., Haupt S., Frazier A., et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021;371:eabf4063. doi: 10.1126/science.abf4063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abf4063</ArticleId><ArticleId IdType="pmc">PMC7919858</ArticleId><ArticleId IdType="pubmed">33408181</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen K.W., Linderman S.L., Moodie Z., Czartoski J., Lai L., Mantus G., Norwood C., Nyhoff L.E., Edara V.V., Floyd K., et al. Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells. Cell Rep. Med. 2021;2:100354. doi: 10.1016/j.xcrm.2021.100354.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2021.100354</ArticleId><ArticleId IdType="pmc">PMC8253687</ArticleId><ArticleId IdType="pubmed">34250512</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung J.H., Rha M.S., Sa M., Choi H.K., Jeon J.H., Seok H., Park D.W., Park S.H., Jeong H.W., Choi W.S., et al. SARS-CoV-2-specific T cell memory is sustained in COVID-19 convalescent patients for 10 months with successful development of stem cell-like memory T cells. Nat. Commun. 2021;12:4043. doi: 10.1038/s41467-021-24377-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-24377-1</ArticleId><ArticleId IdType="pmc">PMC8245549</ArticleId><ArticleId IdType="pubmed">34193870</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng O.W., Chia A., Tan A.T., Jadi R.S., Leong H.N., Bertoletti A., Tan Y.J. Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection. Vaccine. 2016;34:2008–2014. doi: 10.1016/j.vaccine.2016.02.063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2016.02.063</ArticleId><ArticleId IdType="pmc">PMC7115611</ArticleId><ArticleId IdType="pubmed">26954467</ArticleId></ArticleIdList></Reference><Reference><Citation>Grant R.A., Morales-Nebreda L., Markov N.S., Swaminathan S., Querrey M., Guzman E.R., Abbott D.A., Donnelly H.K., Donayre A., Goldberg I.A., et al. Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia. Nature. 2021;590:635–641. doi: 10.1038/s41586-020-03148-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-03148-w</ArticleId><ArticleId IdType="pmc">PMC7987233</ArticleId><ArticleId IdType="pubmed">33429418</ArticleId></ArticleIdList></Reference><Reference><Citation>Szabo P.A., Dogra P., Gray J.I., Wells S.B., Connors T.J., Weisberg S.P., Krupska I., Matsumoto R., Poon M.M.L., Idzikowski E., et al. Longitudinal profiling of respiratory and systemic immune responses reveals myeloid cell-driven lung inflammation in severe COVID-19. Immunity. 2021;54:797–814.e6. doi: 10.1016/j.immuni.2021.03.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2021.03.005</ArticleId><ArticleId IdType="pmc">PMC7951561</ArticleId><ArticleId IdType="pubmed">33765436</ArticleId></ArticleIdList></Reference><Reference><Citation>Poon M.M.L., Rybkina K., Kato Y., Kubota M., Matsumoto R., Bloom N.I., Zhang Z., Hastie K.M., Grifoni A., Weiskopf D., et al. SARS-CoV-2 infection generates tissue-localized immunological memory in humans. Sci. Immunol. 2021;6:eabl9105. doi: 10.1126/sciimmunol.abl9105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abl9105</ArticleId><ArticleId IdType="pmc">PMC8626868</ArticleId><ArticleId IdType="pubmed">34618554</ArticleId></ArticleIdList></Reference><Reference><Citation>Roukens A.H.E., Pothast C.R., Konig M., Huisman W., Dalebout T., Tak T., Azimi S., Kruize Y., Hagedoorn R.S., Zlei M., et al. Prolonged activation of nasal immune cell populations and development of tissue-resident SARS-CoV-2-specific CD8(+) T cell responses following COVID-19. Nat. Immunol. 2022;23:23–32. doi: 10.1038/s41590-021-01095-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01095-w</ArticleId><ArticleId IdType="pubmed">34937933</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramirez S.I., Faraji F., Hills L.B., Lopez P.G., Goodwin B., Stacey H.D., Sutton H.J., Hastie K.M., Saphire E.O., Kim H.J., et al. Immunological memory diversity in the human upper airway. Nature. 2024;632:630–636. doi: 10.1038/s41586-024-07748-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-024-07748-8</ArticleId><ArticleId IdType="pubmed">39085605</ArticleId></ArticleIdList></Reference><Reference><Citation>Niessl J., Sekine T., Lange J., Konya V., Forkel M., Maric J., Rao A., Mazzurana L., Kokkinou E., Weigel W., et al. Identification of resident memory CD8(+) T cells with functional specificity for SARS-CoV-2 in unexposed oropharyngeal lymphoid tissue. Sci. Immunol. 2021;6:eabk0894. doi: 10.1126/sciimmunol.abk0894.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abk0894</ArticleId><ArticleId IdType="pmc">PMC10763663</ArticleId><ArticleId IdType="pubmed">34519539</ArticleId></ArticleIdList></Reference><Reference><Citation>Schenkel J.M., Fraser K.A., Vezys V., Masopust D. Sensing and alarm function of resident memory CD8(+) T cells. Nat. Immunol. 2013;14:509–513. doi: 10.1038/ni.2568.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.2568</ArticleId><ArticleId IdType="pmc">PMC3631432</ArticleId><ArticleId IdType="pubmed">23542740</ArticleId></ArticleIdList></Reference><Reference><Citation>Schenkel J.M., Fraser K.A., Beura L.K., Pauken K.E., Vezys V., Masopust D. T cell memory. Resident memory CD8 T cells trigger protective innate and adaptive immune responses. Science. 2014;346:98–101. doi: 10.1126/science.1254536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1254536</ArticleId><ArticleId IdType="pmc">PMC4449618</ArticleId><ArticleId IdType="pubmed">25170049</ArticleId></ArticleIdList></Reference><Reference><Citation>Markov N.S., Ren Z., Senkow K.J., Grant R.A., Gao C.A., Malsin E.S., Sichizya L., Kihshen H., Helmin K.A., Jovisic M., et al. Distinctive evolution of alveolar T cell responses is associated with clinical outcomes in unvaccinated patients with SARS-CoV-2 pneumonia. Nat. Immunol. 2024;25:1607–1622. doi: 10.1038/s41590-024-01914-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-024-01914-w</ArticleId><ArticleId IdType="pmc">PMC11490290</ArticleId><ArticleId IdType="pubmed">39138384</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., Perez Marc G., Moreira E.D., Zerbini C., et al. Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine. N. Engl. J. Med. 2020;383:2603–2615. doi: 10.1056/NEJMoa2034577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden L.R., El Sahly H.M., Essink B., Kotloff K., Frey S., Novak R., Diemert D., Spector S.A., Rouphael N., Creech C.B., et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 2021;384:403–416. doi: 10.1056/NEJMoa2035389.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2035389</ArticleId><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Falsey A.R., Sobieszczyk M.E., Hirsch I., Sproule S., Robb M.L., Corey L., Neuzil K.M., Hahn W., Hunt J., Mulligan M.J., et al. Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine. N. Engl. J. Med. 2021;385:2348–2360. doi: 10.1056/NEJMoa2105290.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2105290</ArticleId><ArticleId IdType="pmc">PMC8522798</ArticleId><ArticleId IdType="pubmed">34587382</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadoff J., Gray G., Vandebosch A., Cardenas V., Shukarev G., Grinsztejn B., Goepfert P.A., Truyers C., Fennema H., Spiessens B., et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against COVID-19. N. Engl. J. Med. 2021;384:2187–2201. doi: 10.1056/NEJMoa2101544.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2101544</ArticleId><ArticleId IdType="pmc">PMC8220996</ArticleId><ArticleId IdType="pubmed">33882225</ArticleId></ArticleIdList></Reference><Reference><Citation>Heath P.T., Galiza E.P., Baxter D.N., Boffito M., Browne D., Burns F., Chadwick D.R., Clark R., Cosgrove C., Galloway J., et al. Safety and Efficacy of NVX-CoV2373 COVID-19 Vaccine. N. Engl. J. Med. 2021;385:1172–1183. doi: 10.1056/NEJMoa2107659.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2107659</ArticleId><ArticleId IdType="pmc">PMC8262625</ArticleId><ArticleId IdType="pubmed">34192426</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanriover M.D., Doganay H.L., Akova M., Guner H.R., Azap A., Akhan S., Kose S., Erdinc F.S., Akalin E.H., Tabak O.F., et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): Interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021;398:213–222. doi: 10.1016/S0140-6736(21)01429-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)01429-X</ArticleId><ArticleId IdType="pmc">PMC8266301</ArticleId><ArticleId IdType="pubmed">34246358</ArticleId></ArticleIdList></Reference><Reference><Citation>Al Kaabi N., Zhang Y., Xia S., Yang Y., Al Qahtani M.M., Abdulrazzaq N., Al Nusair M., Hassany M., Jawad J.S., Abdalla J., et al. Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial. JAMA. 2021;326:35–45. doi: 10.1001/jama.2021.8565.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.8565</ArticleId><ArticleId IdType="pmc">PMC8156175</ArticleId><ArticleId IdType="pubmed">34037666</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldblatt D., Alter G., Crotty S., Plotkin S.A. Correlates of protection against SARS-CoV-2 infection and COVID-19 disease. Immunol. Rev. 2022;310:6–26. doi: 10.1111/imr.13091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imr.13091</ArticleId><ArticleId IdType="pmc">PMC9348242</ArticleId><ArticleId IdType="pubmed">35661178</ArticleId></ArticleIdList></Reference><Reference><Citation>Corbett K.S., Nason M.C., Flach B., Gagne M., O’Connell S., Johnston T.S., Shah S.N., Edara V.V., Floyd K., Lai L., et al. Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. Science. 2021;373:eabj0299. doi: 10.1126/science.abj0299.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abj0299</ArticleId><ArticleId IdType="pmc">PMC8449013</ArticleId><ArticleId IdType="pubmed">34529476</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandrashekar A., Yu J., McMahan K., Jacob-Dolan C., Liu J., He X., Hope D., Anioke T., Barrett J., Chung B., et al. Vaccine protection against the SARS-CoV-2 Omicron variant in macaques. Cell. 2022;185:1549–1555 e1511. doi: 10.1016/j.cell.2022.03.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.03.024</ArticleId><ArticleId IdType="pmc">PMC8926910</ArticleId><ArticleId IdType="pubmed">35427477</ArticleId></ArticleIdList></Reference><Reference><Citation>Kingstad-Bakke B., Lee W., Chandrasekar S.S., Gasper D.J., Salas-Quinchucua C., Cleven T., Sullivan J.A., Talaat A., Osorio J.E., Suresh M. Vaccine-induced systemic and mucosal T cell immunity to SARS-CoV-2 viral variants. Proc. Natl. Acad. Sci. USA. 2022;119:e2118312119. doi: 10.1073/pnas.2118312119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2118312119</ArticleId><ArticleId IdType="pmc">PMC9171754</ArticleId><ArticleId IdType="pubmed">35561224</ArticleId></ArticleIdList></Reference><Reference><Citation>Mateus J., Dan J.M., Zhang Z., Rydyznski Moderbacher C., Lammers M., Goodwin B., Sette A., Crotty S., Weiskopf D. Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells. Science. 2021;374:eabj9853. doi: 10.1126/science.abj9853.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abj9853</ArticleId><ArticleId IdType="pmc">PMC8542617</ArticleId><ArticleId IdType="pubmed">34519540</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarke A., Coelho C.H., Zhang Z., Dan J.M., Yu E.D., Methot N., Bloom N.I., Goodwin B., Phillips E., Mallal S., et al. SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron. Cell. 2022;185:847–859.e811. doi: 10.1016/j.cell.2022.01.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.015</ArticleId><ArticleId IdType="pmc">PMC8784649</ArticleId><ArticleId IdType="pubmed">35139340</ArticleId></ArticleIdList></Reference><Reference><Citation>Goel R.R., Painter M.M., Apostolidis S.A., Mathew D., Meng W., Rosenfeld A.M., Lundgreen K.A., Reynaldi A., Khoury D.S., Pattekar A., et al. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science. 2021;374:abm0829. doi: 10.1126/science.abm0829.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abm0829</ArticleId><ArticleId IdType="pmc">PMC9284784</ArticleId><ArticleId IdType="pubmed">34648302</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z., Mateus J., Coelho C.H., Dan J.M., Moderbacher C.R., Galvez R.I., Cortes F.H., Grifoni A., Tarke A., Chang J., et al. Humoral and cellular immune memory to four COVID-19 vaccines. Cell. 2022;185:2434–2451 e2417. doi: 10.1016/j.cell.2022.05.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.05.022</ArticleId><ArticleId IdType="pmc">PMC9135677</ArticleId><ArticleId IdType="pubmed">35764089</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerrera G., Picozza M., D’Orso S., Placido R., Pirronello M., Verdiani A., Termine A., Fabrizio C., Giannessi F., Sambucci M., et al. BNT162b2 vaccination induces durable SARS-CoV-2-specific T cells with a stem cell memory phenotype. Sci. Immunol. 2021;6:eabl5344. doi: 10.1126/sciimmunol.abl5344.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abl5344</ArticleId><ArticleId IdType="pubmed">34726470</ArticleId></ArticleIdList></Reference><Reference><Citation>Painter M.M., Mathew D., Goel R.R., Apostolidis S.A., Pattekar A., Kuthuru O., Baxter A.E., Herati R.S., Oldridge D.A., Gouma S., et al. Rapid induction of antigen-specific CD4(+) T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination. Immunity. 2021;54:2133–2142.e3. doi: 10.1016/j.immuni.2021.08.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2021.08.001</ArticleId><ArticleId IdType="pmc">PMC8361141</ArticleId><ArticleId IdType="pubmed">34453880</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Y., Cai C., Grifoni A., Muller T.R., Niessl J., Olofsson A., Humbert M., Hansson L., Osterborg A., Bergman P., et al. Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant. Nat. Med. 2022;28:472–476. doi: 10.1038/s41591-022-01700-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01700-x</ArticleId><ArticleId IdType="pmc">PMC8938268</ArticleId><ArticleId IdType="pubmed">35042228</ArticleId></ArticleIdList></Reference><Reference><Citation>Tauzin A., Nayrac M., Benlarbi M., Gong S.Y., Gasser R., Beaudoin-Bussieres G., Brassard N., Laumaea A., Vezina D., Prevost J., et al. A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses. Cell Host Microbe. 2021;29:1137–1150.e6. doi: 10.1016/j.chom.2021.06.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2021.06.001</ArticleId><ArticleId IdType="pmc">PMC8175625</ArticleId><ArticleId IdType="pubmed">34133950</ArticleId></ArticleIdList></Reference><Reference><Citation>Mudd P.A., Minervina A.A., Pogorelyy M.V., Turner J.S., Kim W., Kalaidina E., Petersen J., Schmitz A.J., Lei T., Haile A., et al. SARS-CoV-2 mRNA vaccination elicits a robust and persistent T follicular helper cell response in humans. Cell. 2022;185:603–613.e15. doi: 10.1016/j.cell.2021.12.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.12.026</ArticleId><ArticleId IdType="pmc">PMC8695127</ArticleId><ArticleId IdType="pubmed">35026152</ArticleId></ArticleIdList></Reference><Reference><Citation>Lederer K., Bettini E., Parvathaneni K., Painter M.M., Agarwal D., Lundgreen K.A., Weirick M., Muralidharan K., Castano D., Goel R.R., et al. Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals. Cell. 2022;185:1008–1024.e15. doi: 10.1016/j.cell.2022.01.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.027</ArticleId><ArticleId IdType="pmc">PMC8808747</ArticleId><ArticleId IdType="pubmed">35202565</ArticleId></ArticleIdList></Reference><Reference><Citation>Ewer K.J., Barrett J.R., Belij-Rammerstorfer S., Sharpe H., Makinson R., Morter R., Flaxman A., Wright D., Bellamy D., Bittaye M., et al. T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nat. Med. 2021;27:270–278. doi: 10.1038/s41591-020-01194-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-01194-5</ArticleId><ArticleId IdType="pubmed">33335323</ArticleId></ArticleIdList></Reference><Reference><Citation>Sette A., Crotty S. Immunological memory to SARS-CoV-2 infection and COVID-19 vaccines. Immunol. Rev. 2022;310:27–46. doi: 10.1111/imr.13089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imr.13089</ArticleId><ArticleId IdType="pmc">PMC9349657</ArticleId><ArticleId IdType="pubmed">35733376</ArticleId></ArticleIdList></Reference><Reference><Citation>Oberhardt V., Luxenburger H., Kemming J., Schulien I., Ciminski K., Giese S., Csernalabics B., Lang-Meli J., Janowska I., Staniek J., et al. Rapid and stable mobilization of CD8(+) T cells by SARS-CoV-2 mRNA vaccine. Nature. 2021;597:268–273. doi: 10.1038/s41586-021-03841-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03841-4</ArticleId><ArticleId IdType="pmc">PMC8426185</ArticleId><ArticleId IdType="pubmed">34320609</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang J., Zeng C., Cox T.M., Li C., Son Y.M., Cheon I.S., Wu Y., Behl S., Taylor J.J., Chakraborty R., et al. Respiratory mucosal immunity against SARS-CoV-2 following mRNA vaccination. Sci. Immunol. 2022;7:eadd4853. doi: 10.1126/sciimmunol.add4853.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.add4853</ArticleId><ArticleId IdType="pmc">PMC9348751</ArticleId><ArticleId IdType="pubmed">35857583</ArticleId></ArticleIdList></Reference><Reference><Citation>Pieren D.K.J., Kuguel S.G., Rosado J., Robles A.G., Rey-Cano J., Mancebo C., Esperalba J., Falco V., Buzon M.J., Genesca M. Limited induction of polyfunctional lung-resident memory T cells against SARS-CoV-2 by mRNA vaccination compared to infection. Nat. Commun. 2023;14:1887. doi: 10.1038/s41467-023-37559-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-37559-w</ArticleId><ArticleId IdType="pmc">PMC10074357</ArticleId><ArticleId IdType="pubmed">37019909</ArticleId></ArticleIdList></Reference><Reference><Citation>Robson F., Khan K.S., Le T.K., Paris C., Demirbag S., Barfuss P., Rocchi P., Ng W.L. Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting. Mol. Cell. 2020;79:710–727. doi: 10.1016/j.molcel.2020.07.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2020.07.027</ArticleId><ArticleId IdType="pmc">PMC7402271</ArticleId><ArticleId IdType="pubmed">32853546</ArticleId></ArticleIdList></Reference><Reference><Citation>Planas D., Saunders N., Maes P., Guivel-Benhassine F., Planchais C., Buchrieser J., Bolland W.H., Porrot F., Staropoli I., Lemoine F., et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature. 2022;602:671–675. doi: 10.1038/s41586-021-04389-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04389-z</ArticleId><ArticleId IdType="pubmed">35016199</ArticleId></ArticleIdList></Reference><Reference><Citation>Planas D., Veyer D., Baidaliuk A., Staropoli I., Guivel-Benhassine F., Rajah M.M., Planchais C., Porrot F., Robillard N., Puech J., et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature. 2021;596:276–280. doi: 10.1038/s41586-021-03777-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03777-9</ArticleId><ArticleId IdType="pubmed">34237773</ArticleId></ArticleIdList></Reference><Reference><Citation>VanBlargan L.A., Errico J.M., Halfmann P.J., Zost S.J., Crowe J.E., Jr., Purcell L.A., Kawaoka Y., Corti D., Fremont D.H., Diamond M.S. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. Nat. Med. 2022;28:490–495. doi: 10.1038/s41591-021-01678-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01678-y</ArticleId><ArticleId IdType="pmc">PMC8767531</ArticleId><ArticleId IdType="pubmed">35046573</ArticleId></ArticleIdList></Reference><Reference><Citation>Keeton R., Tincho M.B., Ngomti A., Baguma R., Benede N., Suzuki A., Khan K., Cele S., Bernstein M., Karim F., et al. T cell responses to SARS-CoV-2 spike cross-recognize Omicron. Nature. 2022;603:488–492. doi: 10.1038/s41586-022-04460-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04460-3</ArticleId><ArticleId IdType="pmc">PMC8930768</ArticleId><ArticleId IdType="pubmed">35102311</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J., Chandrashekar A., Sellers D., Barrett J., Jacob-Dolan C., Lifton M., McMahan K., Sciacca M., VanWyk H., Wu C., et al. Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron. Nature. 2022;603:493–496. doi: 10.1038/s41586-022-04465-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04465-y</ArticleId><ArticleId IdType="pmc">PMC8930761</ArticleId><ArticleId IdType="pubmed">35102312</ArticleId></ArticleIdList></Reference><Reference><Citation>Falsey A.R., Frenck R.W., Jr., Walsh E.E., Kitchin N., Absalon J., Gurtman A., Lockhart S., Bailey R., Swanson K.A., Xu X., et al. SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3. N. Engl. J. Med. 2021;385:1627–1629. doi: 10.1056/NEJMc2113468.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2113468</ArticleId><ArticleId IdType="pmc">PMC8461567</ArticleId><ArticleId IdType="pubmed">34525276</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Beltran W.F., St Denis K.J., Hoelzemer A., Lam E.C., Nitido A.D., Sheehan M.L., Berrios C., Ofoman O., Chang C.C., Hauser B.M., et al. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. Cell. 2022;185:457–466.e4. doi: 10.1016/j.cell.2021.12.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.12.033</ArticleId><ArticleId IdType="pmc">PMC8733787</ArticleId><ArticleId IdType="pubmed">34995482</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu L., Vrbicky K., Montefiori D., Huang W., Nestorova B., Chang Y., Carfi A., Edwards D.K., Oestreicher J., Legault H., et al. Immune response to SARS-CoV-2 after a booster of mRNA-1273: An open-label phase 2 trial. Nat. Med. 2022;28:1042–1049. doi: 10.1038/s41591-022-01739-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01739-w</ArticleId><ArticleId IdType="pmc">PMC9117133</ArticleId><ArticleId IdType="pubmed">35241844</ArticleId></ArticleIdList></Reference><Reference><Citation>Muecksch F., Wang Z., Cho A., Gaebler C., Ben Tanfous T., DaSilva J., Bednarski E., Ramos V., Zong S., Johnson B., et al. Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost. Nature. 2022;607:128–134. doi: 10.1038/s41586-022-04778-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04778-y</ArticleId><ArticleId IdType="pmc">PMC9259484</ArticleId><ArticleId IdType="pubmed">35447027</ArticleId></ArticleIdList></Reference><Reference><Citation>Wragg K.M., Lee W.S., Koutsakos M., Tan H.X., Amarasena T., Reynaldi A., Gare G., Konstandopoulos P., Field K.R., Esterbauer R., et al. Establishment and recall of SARS-CoV-2 spike epitope-specific CD4(+) T cell memory. Nat. Immunol. 2022;23:768–780. doi: 10.1038/s41590-022-01175-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-022-01175-5</ArticleId><ArticleId IdType="pubmed">35314848</ArticleId></ArticleIdList></Reference><Reference><Citation>Corradini P., Agrati C., Apolone G., Mantovani A., Giannarelli D., Marasco V., Bordoni V., Sacchi A., Matusali G., Salvarani C., et al. Humoral and T-cell immune response after three doses of mRNA SARS-CoV-2 vaccines in fragile patients: The Italian VAX4FRAIL study. Clin. Infect. Dis. 2022;76:e426–e438. doi: 10.1093/cid/ciac404.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac404</ArticleId><ArticleId IdType="pmc">PMC9213871</ArticleId><ArticleId IdType="pubmed">35607769</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim S.H., Stuart B., Joseph-Pietras D., Johnson M., Campbell N., Kelly A., Jeffrey D., Turaj A.H., Rolfvondenbaumen K., Galloway C., et al. Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study. Nat. Cancer. 2022;3:552–564. doi: 10.1038/s43018-022-00364-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s43018-022-00364-3</ArticleId><ArticleId IdType="pmc">PMC9135622</ArticleId><ArticleId IdType="pubmed">35332334</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z., Muecksch F., Schaefer-Babajew D., Finkin S., Viant C., Gaebler C., Hoffmann H.H., Barnes C.O., Cipolla M., Ramos V., et al. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature. 2021;595:426–431. doi: 10.1038/s41586-021-03696-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03696-9</ArticleId><ArticleId IdType="pmc">PMC8277577</ArticleId><ArticleId IdType="pubmed">34126625</ArticleId></ArticleIdList></Reference><Reference><Citation>Sokal A., Barba-Spaeth G., Fernandez I., Broketa M., Azzaoui I., de La Selle A., Vandenberghe A., Fourati S., Roeser A., Meola A., et al. mRNA vaccination of naive and COVID-19-recovered individuals elicits potent memory B cells that recognize SARS-CoV-2 variants. Immunity. 2021;54:2893–2907.e5. doi: 10.1016/j.immuni.2021.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2021.09.011</ArticleId><ArticleId IdType="pmc">PMC8452492</ArticleId><ArticleId IdType="pubmed">34614412</ArticleId></ArticleIdList></Reference><Reference><Citation>Stamatatos L., Czartoski J., Wan Y.H., Homad L.J., Rubin V., Glantz H., Neradilek M., Seydoux E., Jennewein M.F., MacCamy A.J., et al. mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. Science. 2021;6549:1413–1418. doi: 10.1126/science.abg9175.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abg9175</ArticleId><ArticleId IdType="pmc">PMC8139425</ArticleId><ArticleId IdType="pubmed">33766944</ArticleId></ArticleIdList></Reference><Reference><Citation>Naranbhai V., Nathan A., Kaseke C., Berrios C., Khatri A., Choi S., Getz M.A., Tano-Menka R., Ofoman O., Gayton A., et al. T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals. Cell. 2022;185:1041–1051.e6. doi: 10.1016/j.cell.2022.01.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.029</ArticleId><ArticleId IdType="pmc">PMC8810349</ArticleId><ArticleId IdType="pubmed">35202566</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodda L.B., Morawski P.A., Pruner K.B., Fahning M.L., Howard C.A., Franko N., Logue J., Eggenberger J., Stokes C., Golez I., et al. Imprinted SARS-CoV-2-specific memory lymphocytes define hybrid immunity. Cell. 2022;185:1588–1601.e14. doi: 10.1016/j.cell.2022.03.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.03.018</ArticleId><ArticleId IdType="pmc">PMC8926873</ArticleId><ArticleId IdType="pubmed">35413241</ArticleId></ArticleIdList></Reference><Reference><Citation>Minervina A.A., Pogorelyy M.V., Kirk A.M., Crawford J.C., Allen E.K., Chou C.H., Mettelman R.C., Allison K.J., Lin C.Y., Brice D.C., et al. SARS-CoV-2 antigen exposure history shapes phenotypes and specificity of memory CD8(+) T cells. Nat. Immunol. 2022;23:781–790. doi: 10.1038/s41590-022-01184-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-022-01184-4</ArticleId><ArticleId IdType="pmc">PMC9106845</ArticleId><ArticleId IdType="pubmed">35383307</ArticleId></ArticleIdList></Reference><Reference><Citation>Dykema A.G., Zhang B., Woldemeskel B.A., Garliss C.C., Rashid R., Westlake T., Zhang L., Zhang J., Cheung L.S., Caushi J.X., et al. SARS-CoV-2 vaccination diversifies the CD4+ spike-reactive T cell repertoire in patients with prior SARS-CoV-2 infection. EBioMedicine. 2022;80:104048. doi: 10.1016/j.ebiom.2022.104048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2022.104048</ArticleId><ArticleId IdType="pmc">PMC9073272</ArticleId><ArticleId IdType="pubmed">35533495</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarke A., Zhang Y., Methot N., Narowski T.M., Phillips E., Mallal S., Frazier A., Filaci G., Weiskopf D., Dan J.M., et al. Targets and cross-reactivity of human T cell recognition of common cold coronaviruses. Cell Rep. Med. 2023;4:101088. doi: 10.1016/j.xcrm.2023.101088.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2023.101088</ArticleId><ArticleId IdType="pmc">PMC10242702</ArticleId><ArticleId IdType="pubmed">37295422</ArticleId></ArticleIdList></Reference><Reference><Citation>Neidleman J., Luo X., McGregor M., Xie G., Murray V., Greene W.C., Lee S.A., Roan N.R. mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status. Elife. 2021;10:e72619. doi: 10.7554/eLife.72619.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.72619</ArticleId><ArticleId IdType="pmc">PMC8545397</ArticleId><ArticleId IdType="pubmed">34636722</ArticleId></ArticleIdList></Reference><Reference><Citation>Callaway E. Fast-evolving COVID variants complicate vaccine updates. Nature. 2022;607:18–19. doi: 10.1038/d41586-022-01771-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-022-01771-3</ArticleId><ArticleId IdType="pubmed">35760853</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartsch S.M., O’Shea K.J., John D.C., Strych U., Bottazzi M.E., Martinez M.F., Ciciriello A., Chin K.L., Weatherwax C., Velmurugan K., et al. The potential epidemiologic, clinical, and economic value of a universal coronavirus vaccine: A modelling study. EClinicalMedicine. 2024;68:102369. doi: 10.1016/j.eclinm.2023.102369.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2023.102369</ArticleId><ArticleId IdType="pmc">PMC10965405</ArticleId><ArticleId IdType="pubmed">38545093</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen J. Making broader coronavirus vaccines is a struggle. Science. 2022;377:566–567. doi: 10.1126/science.ade2363.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.ade2363</ArticleId><ArticleId IdType="pubmed">35926025</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolgin E. Pan-coronavirus vaccine pipeline takes form. Nat. Rev. Drug Discov. 2022;21:324–326. doi: 10.1038/d41573-022-00074-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41573-022-00074-6</ArticleId><ArticleId IdType="pubmed">35440811</ArticleId></ArticleIdList></Reference><Reference><Citation>Cankat S., Demael M.U., Swadling L. In search of a pan-coronavirus vaccine: Next-generation vaccine design and immune mechanisms. Cell Mol. Immunol. 2024;21:103–118. doi: 10.1038/s41423-023-01116-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-023-01116-8</ArticleId><ArticleId IdType="pmc">PMC10805787</ArticleId><ArticleId IdType="pubmed">38148330</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen D.C., Hentenaar I.T., Morrison-Porter A., Solano D., Haddad N.S., Castrillon C., Lamothe P.A., Andrews J., Roberts D., Lonial S., et al. The Majority of SARS-CoV-2 Plasma Cells are Excluded from the Bone Marrow Long-Lived Compartment 33 Months after mRNA Vaccination. medRxiv. 2024 doi: 10.1101/2024.03.02.24303242.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2024.03.02.24303242</ArticleId><ArticleId IdType="pubmed">39333316</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L., Fuhlbrigge R.C., Karibian K., Tian T., Kupper T.S. Dynamic programming of CD8+ T cell trafficking after live viral immunization. Immunity. 2006;25:511–520. doi: 10.1016/j.immuni.2006.06.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2006.06.019</ArticleId><ArticleId IdType="pubmed">16973385</ArticleId></ArticleIdList></Reference><Reference><Citation>Louis L., Clark M., Wise M.C., Glennie N., Wong A., Broderick K., Uzonna J., Weiner D.B., Scott P. Intradermal Synthetic DNA Vaccination Generates Leishmania-Specific T Cells in the Skin and Protection against Leishmania major. Infect. Immun. 2019;87:10–1128. doi: 10.1128/IAI.00227-19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.00227-19</ArticleId><ArticleId IdType="pmc">PMC6652766</ArticleId><ArticleId IdType="pubmed">31182618</ArticleId></ArticleIdList></Reference><Reference><Citation>Zens K.D., Chen J.K., Farber D.L. Vaccine-generated lung tissue-resident memory T cells provide heterosubtypic protection to influenza infection. JCI Insight. 2016;1:215. doi: 10.1172/jci.insight.85832.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.85832</ArticleId><ArticleId IdType="pmc">PMC4959801</ArticleId><ArticleId IdType="pubmed">27468427</ArticleId></ArticleIdList></Reference><Reference><Citation>Marinaik C.B., Kingstad-Bakke B., Lee W., Hatta M., Sonsalla M., Larsen A., Neldner B., Gasper D.J., Kedl R.M., Kawaoka Y., et al. Programming Multifaceted Pulmonary T Cell Immunity by Combination Adjuvants. Cell Rep. Med. 2020;1:100095. doi: 10.1016/j.xcrm.2020.100095.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2020.100095</ArticleId><ArticleId IdType="pmc">PMC7508055</ArticleId><ArticleId IdType="pubmed">32984856</ArticleId></ArticleIdList></Reference><Reference><Citation>Lapuente D., Storcksdieck Genannt Bonsmann M., Maaske A., Stab V., Heinecke V., Watzstedt K., Hess R., Westendorf A.M., Bayer W., Ehrhardt C., et al. IL-1beta as mucosal vaccine adjuvant: The specific induction of tissue-resident memory T cells improves the heterosubtypic immunity against influenza A viruses. Mucosal Immunol. 2018;11:1265–1278. doi: 10.1038/s41385-018-0017-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41385-018-0017-4</ArticleId><ArticleId IdType="pubmed">29545648</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin H., Iwasaki A. A vaccine strategy that protects against genital herpes by establishing local memory T cells. Nature. 2012;491:463–467. doi: 10.1038/nature11522.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature11522</ArticleId><ArticleId IdType="pmc">PMC3499630</ArticleId><ArticleId IdType="pubmed">23075848</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernstein D.I., Cardin R.D., Bravo F.J., Awasthi S., Lu P., Pullum D.A., Dixon D.A., Iwasaki A., Friedman H.M. Successful application of prime and pull strategy for a therapeutic HSV vaccine. NPJ Vaccines. 2019;4:33. doi: 10.1038/s41541-019-0129-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-019-0129-1</ArticleId><ArticleId IdType="pmc">PMC6671986</ArticleId><ArticleId IdType="pubmed">31396405</ArticleId></ArticleIdList></Reference><Reference><Citation>Hobbs S.J., Nolz J.C. Targeted Expansion of Tissue-Resident CD8(+) T Cells to Boost Cellular Immunity in the Skin. Cell Rep. 2019;29:2990–2997.e2. doi: 10.1016/j.celrep.2019.10.126.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2019.10.126</ArticleId><ArticleId IdType="pmc">PMC6914228</ArticleId><ArticleId IdType="pubmed">31801067</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Braeckel-Budimir N., Varga S.M., Badovinac V.P., Harty J.T. Repeated Antigen Exposure Extends the Durability of Influenza-Specific Lung-Resident Memory CD8(+) T Cells and Heterosubtypic Immunity. Cell Rep. 2018;24:3374–3382 e3373. doi: 10.1016/j.celrep.2018.08.073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2018.08.073</ArticleId><ArticleId IdType="pmc">PMC6258017</ArticleId><ArticleId IdType="pubmed">30257199</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies B., Prier J.E., Jones C.M., Gebhardt T., Carbone F.R., Mackay L.K. Cutting Edge: Tissue-Resident Memory T Cells Generated by Multiple Immunizations or Localized Deposition Provide Enhanced Immunity. J. Immunol. 2017;198:2233–2237. doi: 10.4049/jimmunol.1601367.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1601367</ArticleId><ArticleId IdType="pubmed">28159905</ArticleId></ArticleIdList></Reference><Reference><Citation>Alu A., Chen L., Lei H., Wei Y., Tian X., Wei X. Intranasal COVID-19 vaccines: From bench to bed. EBioMedicine. 2022;76:103841. doi: 10.1016/j.ebiom.2022.103841.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2022.103841</ArticleId><ArticleId IdType="pmc">PMC8785603</ArticleId><ArticleId IdType="pubmed">35085851</ArticleId></ArticleIdList></Reference><Reference><Citation>Adler J.M., Martin Vidal R., Langner C., Vladimirova D., Abdelgawad A., Kunecova D., Lin X., Nouailles G., Voss A., Kunder S., et al. An intranasal live-attenuated SARS-CoV-2 vaccine limits virus transmission. Nat. Commun. 2024;15:995. doi: 10.1038/s41467-024-45348-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-024-45348-2</ArticleId><ArticleId IdType="pmc">PMC10837132</ArticleId><ArticleId IdType="pubmed">38307868</ArticleId></ArticleIdList></Reference><Reference><Citation>Warner B.M., Yates J.G.E., Vendramelli R., Truong T., Meilleur C., Chan L., Leacy A., Pham P.H., Pei Y., Susta L., et al. Intranasal vaccination with an NDV-vectored SARS-CoV-2 vaccine protects against Delta and Omicron challenges. NPJ Vaccines. 2024;9:90. doi: 10.1038/s41541-024-00870-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-024-00870-8</ArticleId><ArticleId IdType="pmc">PMC11116387</ArticleId><ArticleId IdType="pubmed">38782986</ArticleId></ArticleIdList></Reference><Reference><Citation>Jearanaiwitayakul T., Sunintaboon P., Kittiayuwat A., Limthongkul J., Wathanaphol J., Janhirun Y., Lerdsamran H., Wiriyarat W., Ubol S. Intranasal immunization with the bivalent SARS-CoV-2 vaccine effectively protects mice from nasal infection and completely inhibits disease development. Vaccine. 2024;42:3664–3673. doi: 10.1016/j.vaccine.2024.04.079.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2024.04.079</ArticleId><ArticleId IdType="pubmed">38714446</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulendran B., Arunachalam P., O’Hagan D.T. Emerging concepts in the science of vaccine adjuvants. Nat. Rev. Drug Discov. 2021;20:454–475. doi: 10.1038/s41573-021-00163-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-021-00163-y</ArticleId><ArticleId IdType="pmc">PMC8023785</ArticleId><ArticleId IdType="pubmed">33824489</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>